|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3-4
|
|
pubmed:dateCreated |
1993-3-18
|
|
pubmed:abstractText |
Antepartum fetal surveillance is well established in the optimal management of any pregnancy complicated by maternal systemic lupus erythematosus and/or its associated serologic abnormalities. Our experience in antepartum surveillance of the "lupus pregnancy" from 1980 to 1988 is reviewed. An overall perinatal mortality rate of 6.06% compares favorably to the total intrauterine death rate range usually reported for this disease.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1046-7408
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
159-63
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:1285869-Antibodies, Anticardiolipin,
pubmed-meshheading:1285869-Aspirin,
pubmed-meshheading:1285869-Autoimmune Diseases,
pubmed-meshheading:1285869-Female,
pubmed-meshheading:1285869-Fetal Death,
pubmed-meshheading:1285869-Fetal Growth Retardation,
pubmed-meshheading:1285869-Fetal Monitoring,
pubmed-meshheading:1285869-Humans,
pubmed-meshheading:1285869-Infant, Newborn,
pubmed-meshheading:1285869-Lupus Coagulation Inhibitor,
pubmed-meshheading:1285869-Lupus Erythematosus, Systemic,
pubmed-meshheading:1285869-Monitoring, Immunologic,
pubmed-meshheading:1285869-Pregnancy,
pubmed-meshheading:1285869-Pregnancy Complications,
pubmed-meshheading:1285869-Pregnancy Outcome,
pubmed-meshheading:1285869-Sensitivity and Specificity
|
|
pubmed:articleTitle |
Condition specific antepartum testing: systemic lupus erythematosus and associated serologic abnormalities.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, New York Hospital-Cornell Medical Center, New York 10021.
|
|
pubmed:publicationType |
Journal Article
|
